Arnav Mehta, MD PhD
About Arnav Mehta, MD PhD
Arnav Mehta, MD PhD, is a postdoctoral researcher and medical oncologist currently affiliated with Massachusetts General Hospital and Harvard Medical School. His extensive background includes roles at various prestigious institutions and a strong academic foundation in medicine and science.
Current Position at Broad Institute
Arnav Mehta serves as a Postdoctoral Researcher at the Broad Institute of MIT and Harvard since 2020. In this role, he conducts research in the labs of Eric Lander and Nir Hacohen, focusing on advancements in cancer research. His work contributes to the institute's mission of improving human health through innovative scientific research.
Medical and Academic Roles
Since 2022, Arnav Mehta has held multiple positions in the medical field. He works as a Medical Oncologist and Assistant in Medicine at Massachusetts General Hospital. Additionally, he serves as an Instructor in Medicine at Harvard Medical School. These roles reflect his commitment to both clinical practice and medical education.
Consulting Experience
Arnav Mehta has extensive consulting experience in the biotechnology sector. He worked as a Consultant at Abata Therapeutics for five months in 2021, and at Flare Therapeutics from 2021 to 2023 for two years. He also consulted for Asher Biotherapeutics and venBio from 2021 to 2022, and previously at Third Rock Ventures from 2017 to 2022. His consulting roles have provided him with insights into the intersection of research and industry.
Educational Background
Arnav Mehta earned his Doctor of Medicine (MD) from the David Geffen School of Medicine at UCLA, completing his studies from 2008 to 2017. He also holds a Doctor of Philosophy (PhD) in Biology and Biological Engineering from Caltech, where he studied from 2010 to 2015 under Nobel laureate David Baltimore. Additionally, he obtained a Bachelor of Science (BS) in Chemistry and Mathematics from Duke University from 2004 to 2008.
Fellowship and Residency Training
Arnav Mehta completed his hematology/oncology fellowship at both Dana-Farber Cancer Institute and Massachusetts General Hospital from 2019 to 2022. Prior to this, he served as a Resident Physician in Internal Medicine at Massachusetts General Hospital from 2017 to 2019. He also participated in the Stanbury Physician Scientist Pathway during his residency, which emphasizes the integration of research and clinical practice.